[1] Eggermont AMM, Blank CU, Mandala M, et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma. New Engl J Med,2018,378:1789-1801.
[2] Zheng C, Zheng L, Yoo JK, et al. Landscape of infiltrating T cells in liver cancer revealed by single-cell sequencing. Cell,2017,169:1342-1356.
[3] Kapanadze T, Gamrekelashvili J, Ma C, et al. Regulation of accumulation and function of myeloid derived suppressor cells in different murine models of hepatocellular carcinoma. J Hepatol,2013,59: 1007-1013.
[4] Iwata T, Kondo Y, Kimura O, et al. PD-L1+MDSCs are increased in HCC patients and induced by soluble factor in the tumor microenvironment. Sci Rep,2016,6:39296.
[5] Iwata T, Kondo Y, Kimura O, et al. PD-L1+MDSCs are increased in HCC patients and induced by soluble factor in the tumor microenvironment. Sci Rep,2016,6:39296.
[6] Iwata T, Kondo Y, Kimura O, et al. PD-L1+MDSCs are increased in HCC patients and induced by soluble factor in the tumor microenvironment. Sci Rep,2016,6:39296.
[7] Dabrowska AM, Slotwinski R. The immune response to surgery and infection. Cent Eur J Immunol,2014,39:532-537.
[8] Chen L, Sun J, Yang X. Radiofrequency ablation-combined multimodel therapies for hepatocellular carcinoma: current status. Cancer Lett,2016,370:78-84.
[9] Cheng Z, Yang P, Qu S, et al. Risk factors and management for early and late intrahepatic recurrence of solitary hepato-cellular carcinoma after curative resection. HPB (Oxford),2015,17: 422- 427.
[10] Joseph RW, Elassaiss-Schaap J, Kefford R, et al. Baseline tumor size is an independent prognostic factor for overall survival in patients with melanoma treated with pembrolizumab. Clin Cancer Res,2018,24:4960-4967.
[11] Zhang DY, Goossens N, Guo J, et al. A hepatic stellate cell gene expression signature associated with outcomes in hepatitis C cirrhosis and hepatocellular carcinoma after curative resection. Gut,2016,65:1754-1764.
[12] Borel F, Konstantinova P, Jansen PL. Diagnostic and thera-peutic potential of miRNA signatures in patients with hepato-cellular carcinoma. J Hepatol, 2012,56:1371-1383.
[13] Gabrielson A, Wu Y, Wang H, et al. Intratumoral CD3 and CD8 T-cell densities associated with relapse-free survival in HCC. Cancer Immunol Res,2016,4: 419- 430.
[14] Brown ZJ, Fu Q, Ma C, et al. Carnitine palmitoyltransferase gene upregulation by linoleic acid induces CD4+ T cell apoptosis promoting HCC development. Cell Death Dis,2018,9:620.
[15] Mehta N, Heimbach J, Harnois DM, et al. Validation of a risk estimation of tumor recurrence after transplant (RETREAT) score for hepatocellular carcinoma recurrence after liver transplant. JAMA Oncol,2017,3: 493-500.
[16] Kuo JC, Lilly LB, Hogg D. Immune checkpoint inhibitor therapy in a liver transplant recipient with a rare subtype of melanoma: a case report and literature review. Melanoma Res,2018,28: 61-64.
[17] Sia D, Jiao Y, Martinez-Quetglas I, et al. Identification of an immune-specific class of hepatocellular carcinoma, based on molecular features. Gastroenterology,2017,153:812-826.
[18] Calderaro J, Rousseau B, Amaddeo G, et al. Programmed death ligand 1 expression in hepatocellular carcinoma: relationship with clinical and pathological features. Hepatology,2016,64:2038-2046. |
